Luis Guillermo Herrera-Jiménez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Luis Guillermo Herrera-Jiménez has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Esteban Zavaleta-Monestel
Hospital Pharmacy Section, International Pharmaceutical Federation, The Hague, ZH, The Netherlands
10 shared publications - Jeaustin Mora-Jiménez
Health Research Department, Clínica Bíblica, San José 1307-1000, Costa Rica
10 shared publications - Sebastián Arguedas-Chacón
Health Research Department, Clínica Bíblica, San José 1307-1000, Costa Rica
9 shared publications - José Andrés Castro-Gamboa
Pharmacy Department, University of Costa Rica, San José 11501-2060, Costa Rica
6 shared publications - José Miguel Chaverri-Fernández
Department of Pharmacy, University of Costa Rica, San Jose 11501-2060, Costa Rica
6 shared publications - Kevin Cruz-Mora
Pharmacy Department, Clínica Bíblica, San José 1307-1000, Costa Rica
5 shared publications
Latest Publications
- Open Access
- 3 October 2026
- Published by MDPI AG in Psychoactives
- Vol. 5 (4) , 27
Private-Sector Sales Trends of Antidepressants and Antipsychotics in Costa Rica, 2022–2026: An Aggregate Analysis by Active Ingredient
Aggregated pharmaceutical sales data can characterize apparent medication consumption and changes in market composition, although they do not represent individual prescribing or patient exposure. This study described private-sector sales trends of antidepressants and antipsychotics in Costa Rica from moving annual total (MAT) February 2022 to MAT February 2026. An observational, descriptive, longitudinal study was conducted using aggregated IQVIA sales data. Total defined daily doses (DDDs) sold were analyzed as the primary indicator, complemented by units sold and analyses by therapeutic group and active ingredient. Antidepressant DDDs increased from 15,299,281 to 17,976,312 (+17.5%), whereas antipsychotic DDDs increased from 1,078,635 to 1,476,810 (+36.9%). In 2026, escitalopram and sertraline had the highest DDD volumes among antidepressants, while quetiapine was the leading antipsychotic. Desvenlafaxine was the largest contributor to net antidepressant growth, whereas aripiprazole and lurasidone contributed substantially to antipsychotic growth. Overall, private-sector sales of both therapeutic groups increased, with distinct patterns across active ingredients. These findings provide a baseline for pharmaceutical market surveillance but should not be interpreted as estimates of total national consumption, public-sector utilization, individual prescribing, clinical indications, or actual patient exposure.
- 3 October 2026
- Published by MDPI AG in Psychoactives
- Vol. 5 (4) , 27
Open AccessPrivate-Sector Sales Trends of Antidepressants and Antipsychotics in Costa Rica, 2022–2026: An Aggregate Analysis by Active Ingredient
Aggregated pharmaceutical sales data can characterize apparent medication consumption and changes in market composition, although they do not represent individual prescribing or patient exposure. This study described private-sector sales trends of antidepressants and antipsychotics in Costa Rica from moving annual total (MAT) February 2022 to MAT February 2026. An observational, descriptive, longitudinal study was conducted using aggregated IQVIA sales data. Total defined daily doses (DDDs) sold were analyzed as the primary indicator, complemented by units sold and analyses by therapeutic group and active ingredient. Antidepressant DDDs increased from 15,299,281 to 17,976,312 (+17.5%), whereas antipsychotic DDDs increased from 1,078,635 to 1,476,810 (+36.9%). In 2026, escitalopram and sertraline had the highest DDD volumes among antidepressants, while quetiapine was the leading antipsychotic. Desvenlafaxine was the largest contributor to net antidepressant growth, whereas aripiprazole and lurasidone contributed substantially to antipsychotic growth. Overall, private-sector sales of both therapeutic groups increased, with distinct patterns across active ingredients. These findings provide a baseline for pharmaceutical market surveillance but should not be interpreted as estimates of total national consumption, public-sector utilization, individual prescribing, clinical indications, or actual patient exposure.
- Open Access
- 12 August 2026
- Published by MDPI AG in Kidney and Dialysis
- Vol. 6 (3) , 54
Contrast Media-Associated Nephrotoxicity: A Narrative Review of Pathophysiology, Risk Factors, Prevention, and Clinical Management
Background: Contrast media are essential tools in diagnostic and interventional imaging, but their relationship with acute kidney injury remains clinically relevant and conceptually debated. This narrative review aimed to synthesize current evidence on contrast media-associated nephrotoxicity, including terminology, epidemiology, pathophysiology, risk stratification, prevention, pharmacotherapeutic management, and clinical decision-making. Methods: A structured literature search was conducted in major biomedical databases and complemented by international guidelines and consensus statements addressing contrast-associated and contrast-induced acute kidney injury in adults exposed to intravascular contrast media. Discussion: Contemporary evidence emphasizes the distinction between contrast-associated acute kidney injury, which reflects a temporal association after exposure, and contrast-induced acute kidney injury, which implies causality. The renal risk directly attributable to modern intravenous iodinated contrast media appears to have been historically overestimated, although clinically relevant risk persists in vulnerable patients. Proposed mechanisms include renal vasoconstriction, medullary hypoxia, oxidative stress, mitochondrial dysfunction, tubular epithelial injury, endothelial dysfunction, and inflammatory or apoptotic pathways. Preventive strategies should be individualized, with isotonic saline remaining the main intervention when indicated, whereas routine pharmacologic prophylaxis is not supported by consistent clinically meaningful benefit. Conclusions: Renal safety in contrast-enhanced imaging requires a balanced approach that minimizes avoidable kidney injury in high-risk patients without unnecessarily delaying clinically indicated diagnostic or therapeutic procedures.
- 12 August 2026
- Published by MDPI AG in Kidney and Dialysis
- Vol. 6 (3) , 54
Open AccessContrast Media-Associated Nephrotoxicity: A Narrative Review of Pathophysiology, Risk Factors, Prevention, and Clinical Management
Background: Contrast media are essential tools in diagnostic and interventional imaging, but their relationship with acute kidney injury remains clinically relevant and conceptually debated. This narrative review aimed to synthesize current evidence on contrast media-associated nephrotoxicity, including terminology, epidemiology, pathophysiology, risk stratification, prevention, pharmacotherapeutic management, and clinical decision-making. Methods: A structured literature search was conducted in major biomedical databases and complemented by international guidelines and consensus statements addressing contrast-associated and contrast-induced acute kidney injury in adults exposed to intravascular contrast media. Discussion: Contemporary evidence emphasizes the distinction between contrast-associated acute kidney injury, which reflects a temporal association after exposure, and contrast-induced acute kidney injury, which implies causality. The renal risk directly attributable to modern intravenous iodinated contrast media appears to have been historically overestimated, although clinically relevant risk persists in vulnerable patients. Proposed mechanisms include renal vasoconstriction, medullary hypoxia, oxidative stress, mitochondrial dysfunction, tubular epithelial injury, endothelial dysfunction, and inflammatory or apoptotic pathways. Preventive strategies should be individualized, with isotonic saline remaining the main intervention when indicated, whereas routine pharmacologic prophylaxis is not supported by consistent clinically meaningful benefit. Conclusions: Renal safety in contrast-enhanced imaging requires a balanced approach that minimizes avoidable kidney injury in high-risk patients without unnecessarily delaying clinically indicated diagnostic or therapeutic procedures.
- Open Access
- 11 August 2026
- Published by American Psychiatric Association Publishing in Psychiatric Research and Clinical Practice
Artificial Intelligence in Psychiatry: Five Decades of Progress and Persistent Translational Challenges
Objective: This review examined the historical development of artificial intelligence (AI) in psychiatry from 1972 to 2025 and identified persistent barriers to clinical translation. Method: The review used a structured source‐identification approach across PubMed/MEDLINE, Web of Science, Google Scholar, ScienceDirect, citation tracking, and targeted historical searches. It synthesized sources qualitatively and organized them chronologically. A structured evidence table summarized representative milestones by era, AI paradigm, clinical task, data modality, validation approach, implementation status, and translational limitation. Results: Psychiatric AI evolved from symbolic simulation and rule‐based expert systems to connectionist models, supervised machine learning, computational psychiatry, digital phenotyping, multimodal monitoring, digital mental health tools, and large language models. Despite increasing computational sophistication, recurring barriers persisted, including uncertain target validity, diagnostic heterogeneity, limited external validation, poor transportability, interpretability challenges, workflow integration, equity, patient trust, and governance. Across eras, technical progress was cyclical rather than linear, with successive waves reproducing unresolved clinical and implementation challenges. Conclusions: The clinical impact of psychiatric AI will likely depend less on algorithmic novelty alone than on clearer clinical targets, prospective validation, implementation trials, patient‐centered evaluation, equity‐sensitive generalizability, and mental health–specific governance. Relevance to Clinical Practice: For routine psychiatric care, AI tools require evidence of clinical validity, transportability, workflow compatibility, patient acceptability, equity, and appropriate governance rather than technical performance alone.
- 11 August 2026
- Published by American Psychiatric Association Publishing in Psychiatric Research and Clinical Practice
Open AccessArtificial Intelligence in Psychiatry: Five Decades of Progress and Persistent Translational Challenges
Objective: This review examined the historical development of artificial intelligence (AI) in psychiatry from 1972 to 2025 and identified persistent barriers to clinical translation. Method: The review used a structured source‐identification approach across PubMed/MEDLINE, Web of Science, Google Scholar, ScienceDirect, citation tracking, and targeted historical searches. It synthesized sources qualitatively and organized them chronologically. A structured evidence table summarized representative milestones by era, AI paradigm, clinical task, data modality, validation approach, implementation status, and translational limitation. Results: Psychiatric AI evolved from symbolic simulation and rule‐based expert systems to connectionist models, supervised machine learning, computational psychiatry, digital phenotyping, multimodal monitoring, digital mental health tools, and large language models. Despite increasing computational sophistication, recurring barriers persisted, including uncertain target validity, diagnostic heterogeneity, limited external validation, poor transportability, interpretability challenges, workflow integration, equity, patient trust, and governance. Across eras, technical progress was cyclical rather than linear, with successive waves reproducing unresolved clinical and implementation challenges. Conclusions: The clinical impact of psychiatric AI will likely depend less on algorithmic novelty alone than on clearer clinical targets, prospective validation, implementation trials, patient‐centered evaluation, equity‐sensitive generalizability, and mental health–specific governance. Relevance to Clinical Practice: For routine psychiatric care, AI tools require evidence of clinical validity, transportability, workflow compatibility, patient acceptability, equity, and appropriate governance rather than technical performance alone.
- Open Access
- 6 July 2026
- Published by MDPI AG in Preprints.org
Contrast Media-Associated Nephrotoxicity: A Narrative Review of Pathophysiology, Risk Factors, Prevention, and Clinical Management
Background: Contrast media are essential tools in diagnostic and interventional imaging, but their relationship with acute kidney injury remains clinically relevant and conceptu-ally debated. This narrative review aimed to synthesize current evidence on contrast me-dia-associated nephrotoxicity, including terminology, epidemiology, pathophysiology, risk stratification, prevention, pharmacotherapeutic management, and clinical deci-sion-making. Methods: A structured literature search was conducted in major biomedical databases and complemented by international guidelines and consensus statements ad-dressing contrast-associated and contrast-induced acute kidney injury in adults exposed to intravascular contrast media. Discussion: Contemporary evidence emphasizes the dis-tinction between contrast-associated acute kidney injury, which reflects a temporal asso-ciation after exposure, and contrast-induced acute kidney injury, which implies causality. The renal risk directly attributable to modern intravenous iodinated contrast media ap-pears to have been historically overestimated, although clinically relevant risk persists in vulnerable patients. Proposed mechanisms include renal vasoconstriction, medullary hy-poxia, oxidative stress, mitochondrial dysfunction, tubular epithelial injury, endothelial dysfunction, and inflammatory or apoptotic pathways. Preventive strategies should be in-dividualized, with isotonic saline remaining the main intervention when indicated, whereas routine pharmacologic prophylaxis is not supported by consistent clinically meaningful benefit. Conclusions: Renal safety in contrast-enhanced imaging requires a balanced approach that minimizes avoidable kidney injury in high-risk patients without unnecessarily delaying clinically indicated diagnostic or therapeutic procedures.
- 6 July 2026
- Published by MDPI AG in Preprints.org
Open AccessContrast Media-Associated Nephrotoxicity: A Narrative Review of Pathophysiology, Risk Factors, Prevention, and Clinical Management
Background: Contrast media are essential tools in diagnostic and interventional imaging, but their relationship with acute kidney injury remains clinically relevant and conceptu-ally debated. This narrative review aimed to synthesize current evidence on contrast me-dia-associated nephrotoxicity, including terminology, epidemiology, pathophysiology, risk stratification, prevention, pharmacotherapeutic management, and clinical deci-sion-making. Methods: A structured literature search was conducted in major biomedical databases and complemented by international guidelines and consensus statements ad-dressing contrast-associated and contrast-induced acute kidney injury in adults exposed to intravascular contrast media. Discussion: Contemporary evidence emphasizes the dis-tinction between contrast-associated acute kidney injury, which reflects a temporal asso-ciation after exposure, and contrast-induced acute kidney injury, which implies causality. The renal risk directly attributable to modern intravenous iodinated contrast media ap-pears to have been historically overestimated, although clinically relevant risk persists in vulnerable patients. Proposed mechanisms include renal vasoconstriction, medullary hy-poxia, oxidative stress, mitochondrial dysfunction, tubular epithelial injury, endothelial dysfunction, and inflammatory or apoptotic pathways. Preventive strategies should be in-dividualized, with isotonic saline remaining the main intervention when indicated, whereas routine pharmacologic prophylaxis is not supported by consistent clinically meaningful benefit. Conclusions: Renal safety in contrast-enhanced imaging requires a balanced approach that minimizes avoidable kidney injury in high-risk patients without unnecessarily delaying clinically indicated diagnostic or therapeutic procedures.
- Open Access
- 22 June 2026
- Published by MDPI AG in Psychiatry International
- Vol. 7 (3) , 140
Peripheral Inflammatory Biomarkers in First-Episode, Drug-Naïve Major Depressive Disorder: A Systematic Review
Major depressive disorder (MDD) is clinically heterogeneous, and peripheral inflammatory biomarkers may help clarify early biological mechanisms before illness chronicity or pharmacologic treatment confound interpretation. This systematic review synthesized evidence on peripheral inflammatory biomarkers in first-episode, drug-naïve major depressive disorder (FEDN-MDD) compared with healthy controls and examined associations with clinical severity. Following PRISMA 2020, searches of PubMed/MEDLINE, Embase, PsycINFO, and Scopus from inception to 19 March 2026 identified 313 records; after screening, 16 publications were included in qualitative synthesis. Studies varied in age group, biological matrix, assay platform, and statistical reporting, precluding meta-analysis. The most frequently assessed biomarkers were IL-1β, TNF-α, IL-6, and CRP/hs-CRP. IL-6 showed the clearest recurrent tendency toward elevation in FEDN-MDD, whereas CRP/hs-CRP findings were partially positive but methodologically limited. TNF-α and IL-1β findings were mixed, and clinical correlations with depressive severity were sparse and inconsistent. Overall, the evidence supports heterogeneous early immune dysregulation in a subset of patients with FEDN-MDD rather than a single reproducible inflammatory signature. Peripheral inflammatory biomarkers should currently be considered research tools for biological stratification and mechanistic hypothesis generation, pending larger standardized longitudinal studies.
- 22 June 2026
- Published by MDPI AG in Psychiatry International
- Vol. 7 (3) , 140
Open AccessPeripheral Inflammatory Biomarkers in First-Episode, Drug-Naïve Major Depressive Disorder: A Systematic Review
Major depressive disorder (MDD) is clinically heterogeneous, and peripheral inflammatory biomarkers may help clarify early biological mechanisms before illness chronicity or pharmacologic treatment confound interpretation. This systematic review synthesized evidence on peripheral inflammatory biomarkers in first-episode, drug-naïve major depressive disorder (FEDN-MDD) compared with healthy controls and examined associations with clinical severity. Following PRISMA 2020, searches of PubMed/MEDLINE, Embase, PsycINFO, and Scopus from inception to 19 March 2026 identified 313 records; after screening, 16 publications were included in qualitative synthesis. Studies varied in age group, biological matrix, assay platform, and statistical reporting, precluding meta-analysis. The most frequently assessed biomarkers were IL-1β, TNF-α, IL-6, and CRP/hs-CRP. IL-6 showed the clearest recurrent tendency toward elevation in FEDN-MDD, whereas CRP/hs-CRP findings were partially positive but methodologically limited. TNF-α and IL-1β findings were mixed, and clinical correlations with depressive severity were sparse and inconsistent. Overall, the evidence supports heterogeneous early immune dysregulation in a subset of patients with FEDN-MDD rather than a single reproducible inflammatory signature. Peripheral inflammatory biomarkers should currently be considered research tools for biological stratification and mechanistic hypothesis generation, pending larger standardized longitudinal studies.
- 29 May 2026
- Published by Hospital Clinica Biblica in Crónicas científicas
- Vol. 30 (2) , 11-14
La recaída temprana del mieloma múltiple después de MajesTEC-3: menos espera, más preparación
MajesTEC-3 marca un punto de inflexión en el tratamiento del mieloma múltiple recaído o refractario en recaída temprana. En pacientes con una a tres líneas previas, sin exposición previa a BCMA y sin refractariedad a anti-CD38, la combinación de teclistamab y daratumumab mostró una superioridad clínicamente contundente frente a tripletes basados en daratumumab elegidos por el investigador. La supervivencia libre de progresión estimada a 36 meses, las tasas de respuesta completa estricta, la negatividad de enfermedad mínima residual y la supervivencia global respaldan un cambio en la secuenciación terapéutica: las terapias biespecíficas ya no deben reservarse automáticamente para fases tardías de la enfermedad. El argumento central no es solo de eficacia, sino también biológico. Cada recaída implica pérdida de pacientes elegibles, toxicidad acumulada y deterioro progresivo de la competencia inmunitaria, factores que pueden limitar el beneficio de las terapias redirigidas a células T cuando se administran demasiado tarde. Sin embargo, adelantar estos tratamientos exige reconocer con seriedad su perfil de seguridad. En MajesTEC-3, el síndrome de liberación de citocinas fue frecuente pero manejable, mientras que las infecciones graves y mortales subrayan la necesidad de profilaxis, reposición de IgG, vigilancia infecciosa y monitorización sistemática. La reducción de infecciones tras la enmienda del protocolo refuerza que la seguridad depende tanto del fármaco como de la infraestructura asistencial. Después de MajesTEC-3, la pregunta ya no es si los biespecíficos pueden adelantarse, sino si los centros están preparados para administrarlos de manera segura, coordinada y responsable.
- 29 May 2026
- Published by Hospital Clinica Biblica in Crónicas científicas
- Vol. 30 (2) , 11-14
La recaída temprana del mieloma múltiple después de MajesTEC-3: menos espera, más preparación
MajesTEC-3 marca un punto de inflexión en el tratamiento del mieloma múltiple recaído o refractario en recaída temprana. En pacientes con una a tres líneas previas, sin exposición previa a BCMA y sin refractariedad a anti-CD38, la combinación de teclistamab y daratumumab mostró una superioridad clínicamente contundente frente a tripletes basados en daratumumab elegidos por el investigador. La supervivencia libre de progresión estimada a 36 meses, las tasas de respuesta completa estricta, la negatividad de enfermedad mínima residual y la supervivencia global respaldan un cambio en la secuenciación terapéutica: las terapias biespecíficas ya no deben reservarse automáticamente para fases tardías de la enfermedad. El argumento central no es solo de eficacia, sino también biológico. Cada recaída implica pérdida de pacientes elegibles, toxicidad acumulada y deterioro progresivo de la competencia inmunitaria, factores que pueden limitar el beneficio de las terapias redirigidas a células T cuando se administran demasiado tarde. Sin embargo, adelantar estos tratamientos exige reconocer con seriedad su perfil de seguridad. En MajesTEC-3, el síndrome de liberación de citocinas fue frecuente pero manejable, mientras que las infecciones graves y mortales subrayan la necesidad de profilaxis, reposición de IgG, vigilancia infecciosa y monitorización sistemática. La reducción de infecciones tras la enmienda del protocolo refuerza que la seguridad depende tanto del fármaco como de la infraestructura asistencial. Después de MajesTEC-3, la pregunta ya no es si los biespecíficos pueden adelantarse, sino si los centros están preparados para administrarlos de manera segura, coordinada y responsable.
- 29 May 2026
- Published by Hospital Clinica Biblica in Crónicas científicas
- Vol. 30 (2) , 30-39
Consideraciones Éticas en la Investigación Psiquiátrica: Estudios en Pacientes con Esquizofrenia Institucionalizados en EE.UU (1940-1975) y su Influencia en la Regulación Bioética
Este trabajo analiza la investigación biomédica realizada entre 1940 y 1975 en pacientes con esquizofrenia institucionalizados en hospitales psiquiátricos de Estados Unidos, partiendo de la hipótesis de que la ausencia de protocolos éticos estandarizados permitió su utilización sistemática en estudios experimentales, lo que finalmente condujo a la creación de mecanismos regulatorios como las Institutional Review Boards (IRB). Se discute cómo el contexto histórico de la psiquiatría asilar, la percepción de los pacientes como “material clínico disponible” y la falta de derechos civiles facilitaron la realización de experimentos farmacológicos e intervenciones invasivas (como la administración de neurolépticos, LSD, lobotomía y terapia electroconvulsiva) frecuentemente sin consentimiento informado ni supervisión ética externa. La revisión de literatura y fuentes históricas evidencia que, aunque estos estudios contribuyeron al desarrollo de la psicofarmacología y la transformación de la psiquiatría moderna, lo hicieron a costa de graves violaciones a los derechos humanos y la dignidad de los pacientes. Como resultado, las denuncias y cuestionamientos éticos derivados de estas prácticas impulsaron la creación de marcos regulatorios y la implementación obligatoria de las IRB, estableciendo la necesidad de supervisión ética, consentimiento informado genuino y protección de poblaciones vulnerables en la investigación biomédica contemporánea.
- 29 May 2026
- Published by Hospital Clinica Biblica in Crónicas científicas
- Vol. 30 (2) , 30-39
Consideraciones Éticas en la Investigación Psiquiátrica: Estudios en Pacientes con Esquizofrenia Institucionalizados en EE.UU (1940-1975) y su Influencia en la Regulación Bioética
Este trabajo analiza la investigación biomédica realizada entre 1940 y 1975 en pacientes con esquizofrenia institucionalizados en hospitales psiquiátricos de Estados Unidos, partiendo de la hipótesis de que la ausencia de protocolos éticos estandarizados permitió su utilización sistemática en estudios experimentales, lo que finalmente condujo a la creación de mecanismos regulatorios como las Institutional Review Boards (IRB). Se discute cómo el contexto histórico de la psiquiatría asilar, la percepción de los pacientes como “material clínico disponible” y la falta de derechos civiles facilitaron la realización de experimentos farmacológicos e intervenciones invasivas (como la administración de neurolépticos, LSD, lobotomía y terapia electroconvulsiva) frecuentemente sin consentimiento informado ni supervisión ética externa. La revisión de literatura y fuentes históricas evidencia que, aunque estos estudios contribuyeron al desarrollo de la psicofarmacología y la transformación de la psiquiatría moderna, lo hicieron a costa de graves violaciones a los derechos humanos y la dignidad de los pacientes. Como resultado, las denuncias y cuestionamientos éticos derivados de estas prácticas impulsaron la creación de marcos regulatorios y la implementación obligatoria de las IRB, estableciendo la necesidad de supervisión ética, consentimiento informado genuino y protección de poblaciones vulnerables en la investigación biomédica contemporánea.
- 29 May 2026
- Published by Hospital Clinica Biblica in Crónicas científicas
- Vol. 30 (2) , 5-10
Miopericarditis aguda asociada a rituximab: reporte de un caso de un paciente con tricoleucemia
La miopericarditis es una enfermedad inflamatoria que compromete tanto el saco pericárdico como el miocardio, representando una causa infrecuente de dolor torácico no isquémico en los servicios de urgencias. Aunque el rituximab es un anticuerpo monoclonal esencial para tratar enfermedades hematológicas como la tricoleucemia, la aparición de eventos adversos cardiovasculares graves es poco común en la literatura médica. Se presenta el caso de un hombre de 46 años con antecedente de tricoleucemia en recidiva que, tras la administración de su segunda dosis de rituximab, desarrolló un cuadro agudo de fiebre, dolor retroesternal, disnea y distensión abdominal. Las evaluaciones iniciales mostraron niveles elevados de troponina (891 pg/mL), pro-BNP (1587 pg/mL) y proteína C reactiva (165 mg/L). Pese a que el ecocardiograma inicial no reportó alteraciones estructurales, el paciente sufrió un rápido deterioro clínico con desaturación de oxígeno hasta el 83%, taquicardia sinusal, disminución de la fracción de eyección y derrame pericárdico leve. Debido a la severidad del compromiso, fue trasladado a la Unidad de Cuidados Intensivos para soporte ventilatorio y hemodinámico. Tras excluir etiologías infecciosas mediante hemocultivos y pruebas virales, se instauró un esquema con corticosteroides intravenosos, diuréticos y soporte neurohormonal. El paciente presentó una mejoría progresiva y fue egresado al séptimo día con manejo ambulatorio. Este caso resalta que la miopericarditis asociada a rituximab debe considerarse en el diagnóstico diferencial ante síntomas cardiorrespiratorios post-infusión. Asimismo, subraya que un ecocardiograma inicial normal no descarta una evolución desfavorable posterior, siendo el inicio precoz de esteroides fundamental para una recuperación exitosa.
- 29 May 2026
- Published by Hospital Clinica Biblica in Crónicas científicas
- Vol. 30 (2) , 5-10
Miopericarditis aguda asociada a rituximab: reporte de un caso de un paciente con tricoleucemia
La miopericarditis es una enfermedad inflamatoria que compromete tanto el saco pericárdico como el miocardio, representando una causa infrecuente de dolor torácico no isquémico en los servicios de urgencias. Aunque el rituximab es un anticuerpo monoclonal esencial para tratar enfermedades hematológicas como la tricoleucemia, la aparición de eventos adversos cardiovasculares graves es poco común en la literatura médica. Se presenta el caso de un hombre de 46 años con antecedente de tricoleucemia en recidiva que, tras la administración de su segunda dosis de rituximab, desarrolló un cuadro agudo de fiebre, dolor retroesternal, disnea y distensión abdominal. Las evaluaciones iniciales mostraron niveles elevados de troponina (891 pg/mL), pro-BNP (1587 pg/mL) y proteína C reactiva (165 mg/L). Pese a que el ecocardiograma inicial no reportó alteraciones estructurales, el paciente sufrió un rápido deterioro clínico con desaturación de oxígeno hasta el 83%, taquicardia sinusal, disminución de la fracción de eyección y derrame pericárdico leve. Debido a la severidad del compromiso, fue trasladado a la Unidad de Cuidados Intensivos para soporte ventilatorio y hemodinámico. Tras excluir etiologías infecciosas mediante hemocultivos y pruebas virales, se instauró un esquema con corticosteroides intravenosos, diuréticos y soporte neurohormonal. El paciente presentó una mejoría progresiva y fue egresado al séptimo día con manejo ambulatorio. Este caso resalta que la miopericarditis asociada a rituximab debe considerarse en el diagnóstico diferencial ante síntomas cardiorrespiratorios post-infusión. Asimismo, subraya que un ecocardiograma inicial normal no descarta una evolución desfavorable posterior, siendo el inicio precoz de esteroides fundamental para una recuperación exitosa.
- Open Access
- 16 May 2026
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 8 (2) , 23
Artificial Intelligence in Helicobacter Pylori Infection: Diagnostic Applications and Emerging Treatment-Related Predictive Uses—A Systematic Review
Background: Artificial intelligence (AI) has shown growing potential in the diagnosis of H. pylori infection, particularly through automated analysis of endoscopic images. Emerging studies have also explored treatment-related predictive applications, although this evidence remains limited. The aim of this systematic review was to synthesize current evidence on the use of AI in H. pylori infection, with the primary emphasis on diagnosis and secondary consideration of predictive therapeutic applications. Methods: A systematic review was conducted in accordance with PRISMA 2020 guidelines through searches in PubMed, ScienceDirect, EBSCO, and the Cochrane Library, including articles published between 2020 and 2025. Six studies that employed deep learning or machine learning models, primarily convolutional neural networks and predictive classifiers, were selected. Results: Artificial intelligence models showed consistent diagnostic performance, with accuracies ranging from 79.2% to 94%, sensitivities from 62.5% to 96%, and specificities from 79.4% to 93.4%. Convolutional neural network-based systems generally demonstrated diagnostic performance comparable to or better than that of human endoscopists, particularly among less experienced operators. Limited evidence suggests a possible role for artificial intelligence in predicting treatment failure; however, this finding is based on a single included study. Conclusions: Artificial intelligence appears to be a promising complementary tool for the diagnosis of H. pylori infection, particularly in endoscopic imaging. However, evidence regarding treatment-related and resistance-related applications remains limited and indirect, and these potential uses should therefore be considered preliminary.
- 16 May 2026
- Published by MDPI AG in Gastrointestinal Disorders
- Vol. 8 (2) , 23
Open AccessArtificial Intelligence in Helicobacter Pylori Infection: Diagnostic Applications and Emerging Treatment-Related Predictive Uses—A Systematic Review
Background: Artificial intelligence (AI) has shown growing potential in the diagnosis of H. pylori infection, particularly through automated analysis of endoscopic images. Emerging studies have also explored treatment-related predictive applications, although this evidence remains limited. The aim of this systematic review was to synthesize current evidence on the use of AI in H. pylori infection, with the primary emphasis on diagnosis and secondary consideration of predictive therapeutic applications. Methods: A systematic review was conducted in accordance with PRISMA 2020 guidelines through searches in PubMed, ScienceDirect, EBSCO, and the Cochrane Library, including articles published between 2020 and 2025. Six studies that employed deep learning or machine learning models, primarily convolutional neural networks and predictive classifiers, were selected. Results: Artificial intelligence models showed consistent diagnostic performance, with accuracies ranging from 79.2% to 94%, sensitivities from 62.5% to 96%, and specificities from 79.4% to 93.4%. Convolutional neural network-based systems generally demonstrated diagnostic performance comparable to or better than that of human endoscopists, particularly among less experienced operators. Limited evidence suggests a possible role for artificial intelligence in predicting treatment failure; however, this finding is based on a single included study. Conclusions: Artificial intelligence appears to be a promising complementary tool for the diagnosis of H. pylori infection, particularly in endoscopic imaging. However, evidence regarding treatment-related and resistance-related applications remains limited and indirect, and these potential uses should therefore be considered preliminary.
- Open Access
- 15 May 2026
- Published by MDPI AG in Kidney and Dialysis
- Vol. 6 (2) , 34
Correction: Zavaleta-Monestel et al. Sodium Zirconium Cyclosilicate in the Therapeutic Management of Hyperkalemia: A Systematic Review of Efficacy and Safety. Kidney Dial. 2026, 6, 19
- 15 May 2026
- Published by MDPI AG in Kidney and Dialysis
- Vol. 6 (2) , 34
Open AccessCorrection: Zavaleta-Monestel et al. Sodium Zirconium Cyclosilicate in the Therapeutic Management of Hyperkalemia: A Systematic Review of Efficacy and Safety. Kidney Dial. 2026, 6, 19